<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> (<z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">FAB M6</z:e>), and <z:hpo ids='HP_0006733'>acute megakaryocytic leukemia</z:hpo> (<z:e sem="disease" ids="C0023462" disease_type="Neoplastic Process" abbrv="">FAB M7</z:e>) have overlapping features </plain></SENT>
<SENT sid="1" pm="."><plain>PROCEDURE: Children without <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> or <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> who were newly diagnosed with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) M6 or M7 were compared to children with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M0-M5 </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> children were entered on the Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group therapeutic research study CCG 2891 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The presentation and outcomes of the 132 children diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (60 children), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">FAB M6</z:e> (19 children), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0023462" disease_type="Neoplastic Process" abbrv="">FAB M7</z:e> (53 children) were similar </plain></SENT>
<SENT sid="4" pm="."><plain>Children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0023462" disease_type="Neoplastic Process" abbrv="">FAB M7</z:e> were diagnosed at a significantly younger age (P = 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, M6, or M7 had significantly lower white blood cell (WBC) counts (P = 0.001), lower peripheral blast counts (P &lt; 0.001), and an increased frequency of -7/7q- (P = 0.003) at presentation </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three groups had significantly inferior overall survival (OS) (P &lt; 0.001) and event free survival (P &lt; 0.001) compared with the 748 children diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0522631" disease_type="Neoplastic Process" abbrv="">FAB M0</z:e>-M5 when assessed from entry on study </plain></SENT>
<SENT sid="7" pm="."><plain>This poor survival was largely attributable to induction <z:hpo ids='HP_0011420'>death</z:hpo> and failure </plain></SENT>
<SENT sid="8" pm="."><plain>However, when assessed from successful completion of induction therapy, the 5-year OS (P = 0.090)(49.1 vs. 56.9%) and disease-free survival (DFS) (P = 0.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C0220621" disease_type="Neoplastic Process" abbrv="">Childhood AML</z:e> <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">FAB M6</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M7 resemble <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in presentation, poor induction success rates, and outcomes </plain></SENT>
</text></document>